To access slide decks or videos, click on the button below.

Slide Decks & Videos

Antibody-drug conjugates: a different kind of cancer therapy

Antibody-drug conjugates (ADCs) offer a potentially new way to treat cancer by combining the proven antigen-specific selectivity and antitumor activity of monoclonal antibodies with the potency of cytotoxic molecules.^1,2 ADCs have the potential to optimize the best features of both components by^2-4

• Increasing the cell-killing potential of monoclonal antibodies
• Conferring higher tumor selectivity and, therefore, increased tolerability while limiting systemic exposure

Taking targeted therapy to the next level

Genentech, a member of the Roche Group, has developed ResearchADCs.com as a primary resource for information about ADCs and their role in the treatment of a variety of cancers. Genentech is aggressively researching ADCs and their potential to play an important role in clinical medicine and to expand the therapeutic options available to patients.^1,2,4

References:

1.

Trail PA, Bianchi AB. Monoclonal antibody drug conjugates in the treatment of cancer. Curr Opin Immunol. 1999;11:584-588.

2.

Wu AM, Senter PD. Arming antibodies: prospects and challenges for immunoconjugates. Nat Biotechnol. 2005;23:1137-1146.

3.

Chari RVJ. Targeted cancer therapy: conferring specificity to cytotoxic drugs. Acc Chem Res.
2008;41:98-107.

4.

Ducry L, Stump B. Antibody–drug conjugates: linking cytotoxic payloads to monoclonal antibodies. Bioconjug Chem.
2010;21:5-13.